anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Carbapenem-resistant Acinetobacter spp. is associated with nosocomial infections in intensive care unit patients, resulting in high mortality. Although Acinetobacter spp. represent a serious public health problem worldwide, there are a few studies related to the presence of carbapenemases in health care facilities and other environmental settings in Ecuador. The main aim of this study was to characterize the carbapenem-resistant Acinetobacter spp. isolates obtained from four hospitals (52) and from five rivers (27) close to Quito. We used the disc diffusion and EDTA sinergy tests to determine the antimicrobial susceptibility and the production of metallo β-lactamases, respectively. We carried out a multiplex PCR of gyrB gene and the sequencing of partial rpoB gene to bacterial species identification. We performed molecular screening of nine carbapenem-resistant genes (blaSPM, blaSIM, blaGIM, blaGES, blaOXA-23, blaOXA-24, blaOXA-51, blaOXA-58, and blaOXA-143) by multiplex PCR, followed by identification using sequencing of blaOXA genes. Our findings showed that carbapenem-resistant A. baumannii were the main species found in health care facilities and rivers. Most of the clinical isolates came from respiratory tract samples and harbored blaOXA-23, blaOXA-366, blaOXA-72, blaOXA-65, blaOXA-70, and blaOXA-143-like genes. The river isolates harbored only the blaOXA-51 and probably blaOXA-259 genes. We concluded that the most predominant type of carbapenem genes among isolates were both blaOXA-23 and blaOXA-65 among A. baumannii clinical isolates.
FIELD: medicine, pharmacy. SUBSTANCE: invention claims thrombolytic agent activating fibrinolysis, the use of 6-amidino-2-naphthyl-4-[(4,5-dihydro-1H-imidazole- -2-yl)-amino]-benzoate or its pharmaceutically acceptable acid addition salts of the formula (I) as indicated agents and methods of treatment of patients with thrombosis and myocardium infarction. Agents showing thrombolytic and effect activating fibrinolysis have effective amount of the compound of the formula (I). Methods of patient treatment involve administration to patient an effective amount of an agent. Agents can contain pharmaceutically acceptable carriers additionally. The claimed agents and methods of patient treatment ensure to dissolve thrombi in blood vessels and so eliminate their obstruction. Agents can be administrated orally that makes advantages as compared with the known preparations of similar effect administrated into blood vessel by catheter. EFFECT: enhanced effectiveness of agents. 12 cl, 3 dwg, 2 tbl, 9 ex
FIELD: agriculture. ^ SUBSTANCE: invention relates to livestock farming. Daily cycle of one or more mammal females is divided into phase of day time with the first light mode with a share of blue light and phase of night time with the second light mode. Animals are milked at least once during night time phase. During night time phase, at least one source of light is used for light mode, which radiates light in the range of wave length of 500 nm or more, and mainly does not radiate light in the range of wave lengths below 500 nm. Produced milk may be processed to make milk products, in particular, dry milk with high content of melatonin. ^ EFFECT: method makes it possible to produce milk and milk products with high content of melatonin, which may be used as biologically active additives to food or as medicinal agents. ^ 3 dwg, 3 ex, 17 cl
The invention discloses a benzyl alcohol ether compound, a preparation method, a preparation and applications thereof. The benzyl alcohol ether compound is a derivative, of which a general formula is represented as the formula (I), and a salt thereof, wherein R is represented as an alkyl compound and a carbonyl compound. The preparation method comprises a step of performing a dehydration reaction between raw materials, comprising ethyl p-hydroxybenzoate, p-hydroxy benzaldehyde, nicotinic acid or triacetyl gallic acid, and 4-((3,5,6-trimethylpyrazine-2-yl)methoxyl)benzyl alcohol to generate a target product. The preparation is a tablet, a capsule, an injection liquid or a freeze-dried powder injection which is prepared from the benzyl alcohol ether compound with addition of pharmaceutically-acceptable auxiliary materials. The applications of the benzyl alcohol ether compound includes an application in preparation of an anticoagulant medicine and an application in preparation of a medicine preventing and/or treating drugs for cardiovascular and cerebrovascular diseases. The preparation method is simple and easy to carry out, is good in repeatability, is less in environmental pollution, and can be used for preparing the compound represented as the following formula in a large scale.
These cases will be recruited prospectively, and receive the intercostal nerve block(s) on operated site(s). Peri-operative injections of 30 ml of 0.25% Bupivacaine each, injected over the 4th, 5th, and 6th ribs on the operated site(s).
Worldwide, more than 130 million infants are born each year and a considerable number of 13.5 million of these children have inbred parents. The present study aimed to investigate the association between parents' consanguinity and chronic illness among their children and grandchildren in India. The nationally representative data, Longitudinal Aging Study in India, 2017-2018, Wave 1 was used for the present study. Bivariate analysis, a probit model, and propensity score estimation were employed to conduct the study. The study observed the highest prevalence of consanguinity marriage in the state of Andhra Pradesh (28%) and the lowest in Kerala (5%) among the south Indian States. People who lived in rural areas, belonged to the richer wealth quintile and Hindu religion were the significant predictors of consanguinity marriage in India. For individuals who were in consanguineous marriages, there was 0.85%, 0.84%, 1.57% 0.43%, 0.34%, and 0.14% chances of their children and grandchildren developing psychotic disorders, heart disease, hypertension stroke, cancer, and diabetes, respectively. Moreover, around 4.55% of the individuals have a history of birth defects or congenital disorders. To address the risk of complicated illnesses due to the consanguinity of marriage, medical, genetic, and social counselling services are required.
We report the case of a woman nearing 70 years old who was admitted to the hospital with a complaint of "epigastric distension for 1 month". Her main signs and symptoms were progressive abdominal distension and occasional abdominal pain. Computed tomography suggested an abdominal mass. She had a surgical history of synovial sarcoma (SS) of the lungs. After admission, she was diagnosed with jejunal SS following a puncture biopsy and laparoscopic surgery. This disease usually occurs in the soft tissues of the limbs, and it is extremely rare for SS to originate in the jejunum. The morphologic heterogeneity of SS overlaps with other tumors and makes the diagnosis particularly difficult. Imaging studies usually lack specificity; however, measuring multiple immunohistochemical markers can greatly assist in the diagnosis and differential diagnosis of SS. This case not only enriches our understanding of SS and describes a rare site of origin, but also emphasizes the importance and challenges of achieving an accurate diagnosis. Immunohistochemical and molecular biological testing have important roles in the definitive diagnosis, highlighting the need for precise and innovative diagnostic and therapeutic approaches in SS.
RizaFilm should not be given to patients with ischemic or vasospastic coronary artery disease. There have been rare reports of serious cardiac adverse reactions, including acute myocardial infarction, occurring within a few hours following administration of rizatriptan benzoate. Some of these reactions occurred in patients without known coronary artery disease (CAD). 5-HT1 agonists, including RizaFilm may cause coronary artery vasospasm (Prinzmetal's Angina), even in patients without a history of CAD.

Perform a cardiovascular evaluation in triptan-naïve patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) before receiving RizaFilm. If there is evidence of CAD or coronary artery vasospasm, RizaFilm is contraindicated. For patients with multiple cardiovascular risk factors who have a negative cardiovascular evaluation, consider administering the first RizaFilm dose in a medically supervised setting and performing an electrocardiogram (ECG) immediately following RizaFilm administration. For such patients, consider periodic cardiovascular evaluation in intermittent long-term users of RizaFilm.
FIELD: organic chemistry. SUBSTANCE: invention proposes derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid of the formula (I)   where R 3b  is azide or group -NR 6b R 7b  being R 6b  is hydrogen, C 1-6 --alkyl or allyl; R 46  is NHCOR 9b  where R 9b  is C 1-6 -alkyl, or their pharmaceutically acceptable salts and ester salts. Method of synthesis of compounds of the formula (I) involves interaction of derivative of the formula (III)   protected by carboxy- and hydroxy-groups where R 4b  has above indicated value; OL - group to be removed with nucleophilic group followed by conversion to amine, guanidine, salt, ester of ester salt. Invention proposes also pharmaceutical composition showing antiviral activity with respect to ortho-paramyxoviruses that contains a compound of the formula (I) as an active component taken at effective amount. Invention proposes also a method of treatment of mammals including human with viral infections by administration of compounds of the formula (I) at the dose 0.01-750 mg/kg body mass/day in respiratory ways or by intranasal route. EFFECT: improved method of synthesis, enhanced effectiveness of compounds synthesized. 15 cl, 15 dwg, 3 tbl, 24 ex
Participants assigned to the control intervention will continue to pursue standard care (a waitlist). Waitlist control subjects will be offered the opportunity to receive the intervention following completion of the final 6-month follow up outcome assessment.
Patients will undergo bone marrow aspiration using the Jamshidi bone marrow aspiration needle. This needle is the traditional trocar with an open end. 50-60 mL will be collected and concentrated with a centrifuge.
The study group consisted of 40 volunteers women with PCOS (aged 18- 40 years, BMI, 18-44kg/m2) who attended the obstetrics and gynecology clinic for the treatment of menstrual irregularities and hirsutism.The patients were treated with 0.6-0.8 mg/kg oral isotretinoin up to a total dose of 120-150 mg/kg. Treatment was started at 20 mg/day and gradually increased to the maximum of 40 mg/day. The patients were monitored monthly during isotretinoin treatment.
BACKGROUND: Rheumatoid arthritis (RA) remains a devastating autoimmune disease characterized by joint damage, inflammation, and disability. This study investigates the function of lymphocyte antigen 96 (LY96) in the inflammatory response in RA and explores its regulatory mechanism.
METHODS: A mouse model of RA was developed using type II collagen, and the LY96 expression in the ankle joint tissue was determined. Upstream regulators targeting LY96 were investigated using bioinformatics, followed by chromatin immunoprecipitation and luciferase reporter assays for validation. Gain- or loss-of-functions of LY96 and forkhead box A2 (FOXA2) were performed to analyze their roles in arthritis score, pathological changes, and inflammatory responses in mice. The effects of FOXA2 and LY96 on pro-inflammatory activation of macrophages were additionally investigated in vitro using a mouse RAW264.7 macrophage model with lipopolysaccharide treatment.
RESULTS: LY96 mRNA and protein (MD-2) levels were increased in the RA mice. Knockdown of LY96 alleviated arthritis severity, joint deformities, inflammation, and cartilage destruction in mice. In vitro, the LY96 knockdown reduced the pro-inflammatory activation of RAW264.7 macrophages by inhibiting the TLR4/NF-κB inflammatory signaling transduction. FOXA2 was identified as a transcriptional repressor of LP96 poorly expressed in RA. Overexpression of FOXA2 similarly alleviated inflammation and reduced M1-type macrophages in vivo and in vitro. However, these changes were reversed by the additional LY96 upregulation.
CONCLUSION: This study suggests that FOXA2 represses LY96 transcription to inhibit the TLR4/NF-κB signaling transduction, thus reducing pro-inflammatory activation of macrophages in the context of RA.
When converting from AVINZA to parenteral opioids, it is best to calculate an equivalent parenteral dose and then initiate treatment at half of this calculated value. As an example, an estimated total 24-hour parenteral morphine requirement of a patient receiving AVINZA is one-third of the dose of AVINZA. This is because the oral bioavailability of morphine is one-third that of parenteral morphine. This estimated dose should then be divided in half, and this last calculated dose is the total daily dose. This value should be further divided by six if the desire is to dose with parenteral morphine every four hours. 

Consider a patient taking 360 mg of AVINZA daily. First, divide by 3, to account for differences in bioavailability between oral and parenteral morphine. This new figure, 120 mg, is the estimated total 24-hour requirement of parenteral morphine. Dividing by 2, the result gives the total daily dose of 60 mg. If it is decided to administer the drug at four-hour intervals, then administer 10 mg (60 divided by 6) every four hours.

Although this approach may require a dosage increase in the first 24 hours for many patients, this method is recommended, as it is less likely to result in overdose. Overdose is more likely to occur when administering an equivalent dose of parenteral morphine without titration. Provision for break-through pain should be made.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: present group of inventions refers to medicine, namely to pharmacy and concerns an oral systemic drug delivery system. As such, bolus consisting of semisolid gel (BSSG) are used. BSSG contains a homogeneous matrix of semisolid gel containing agar and an effective amount of one or more active ingredients. The semisolid gel is characterised by such durability value that a sample having a diameter within 12 to 14 mm and thickness 4 to 6 mm requires applying force 1 to 15 Newton for disk squashing by 1 mm with each BSSG containing 0.1 wt % to 3 wt % of agar and has water content within 30% to 90%. ^ EFFECT: agent used in the present group of inventions allows accelerating drug delivery to blood flow, eliminating a parenteral administration mode, due to semisolid gel decomposition in an oral cavity, including in the absence of drinking water. ^ 19 cl, 2 tbl, 10 ex, 4 dwg
Hepatic stellate cells (HSCs) are pericytes of the liver responsible for liver fibrosis and cirrhosis, which are the end stages of chronic liver diseases. TGF-β activates HSCs, leading to the differentiation of myofibroblasts in the process of liver fibrosis. While the heterogeneity of HSCs is appreciated in the fibrotic liver, it remains elusive which HSC subsets mainly contribute to fibrosis. Here, we show that the expression of the pericyte marker FoxD1 specifically marks a subset of HSCs in FoxD1-fate tracer mice. HSCs fate-mapped by FoxD1 were preferentially localized in the portal and peripheral areas of both the homeostatic and fibrotic liver induced by carbon tetrachloride. Furthermore, the deletion of Cbfβ, which is necessary for TGF-β signaling, in FoxD1-expressing cells ameliorated liver fibrosis. Thus, we identified an HSC subset that preferentially responds to liver injuries.
Eligible patients with clinical stage Ⅱ-Ⅲ NSCLC will receive dynamic PET-CT before and after 3 cycles neoadjuvant pembrolizumab plus chemotherapy, then patients receive surgical resection. Changes in tumor size were evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Net uptake rate constant of FDG-Ki value based on dynamic PET will be calculated to evaluate Ki changes before and after treatment. Pathological tumor response were evaluated according to IASLC recommendations. Dynamic PET will be compared with RECIST whether it can better predict the pathological tumor response and disease free survival.
This was the case of a male patient in his 60s, who suddenly collapsed. When the ambulance team arrived, the initial waveform was pulseless electrical activity; accordingly, a supraglottic airway device was inserted, and the patient was immediately transported to a referring hospital. On arrival, the patient resumed spontaneous circulation, the patient was diagnosed with Stanford type B acute aortic dissection and was referred to the author's hospital, where diffuse swelling of the anterior cervical region was revealed. CT performed by the previous hospital revealed compression of the trachea. The cause of cardiac arrest was considered to be severe airway stenosis secondary to a retropharyngeal haematoma associated with Stanford type B acute aortic dissection. Stanford type B acute aortic dissection can be complicated by retropharyngeal haematomas, which can lead to airway obstruction and even cardiac arrest. This condition also requires careful airway examination.
The incidence of AML increases with age, and current treatment options for the older patient population with newly diagnosed AML (AML \>= 60) is limited, all with poor outcomes. AML \>= 60 patients are more likely to have poor-risk cytogenetics abnormalities, and many have a preceding myelodysplastic syndrome (MDS). Traditional induction chemotherapy approaches in AML with cytarabine and anthracyclines yield remissions in 45-60% of AML \>= 60, however the vast majority of these patients relapse with a median survival of about 9 months. These patients are rarely candidates for potentially curative allogeneic stem cell transplantation. Many untreated AML \>= 60 patients are not candidates for aggressive therapy, and those who do receive therapy have a significant induction mortality of 10-20%, and significant hematologic toxicity occurs in over 30%, with no change in overall survival compared with supportive care. AML \>= 60 patients with favorable risk cytogenetics have a modest improvement in prognosis, for example with a 5 year overall survival of \~20%, compared with 0% in other cytogenetic categories. Thus, all eligible patients with AML \>= 60 should be recommended a clinical trial, regardless of whether they would be offered generally ineffective traditional induction chemotherapy. More effective and less toxic therapies are needed for the treatment of AML in this older patient population, indeed the preferred first line therapy in the national cancer center network (NCCN) guidelines for AML is a clinical trial.

In trials of lenalidomide in patients with MDS the dose of lenalidomide has been reduced for myelotoxicity and/or thrombocytopenia. However, current paradigms for the therapy of acute myeloid leukemia are based on using high doses of myelosuppressive chemotherapy and supporting the patient through a 4-5 weeks period of neutropenia/thrombocytopenia in an attempt to eliminate the malignant clone. Based on its efficacy in the related myeloid disorder MDS, and the close relationship between MDS and AML in patients \> 60, this trial employs the same paradigm of myelosuppressive therapy using high dose lenalidomide instead of chemotherapy. Importantly, within the MDS trials using low doses of lenalidomide, responses were observed in 3/9 (33%) of patients with excess blasts (RAEB/RAEB-t), which are now classified as evolving into AML or AML. This suggests that the therapeutic effect of lenalidomide occurs in the setting of a large percentage of blasts, such as AML, although the dose and schedule of lenalidomide administration is different. The response of AML \>= 60 patients to the proposed high dose lenalidomide regimen is unknown. Following high dose lenalidomide, in those patients that have a response, we propose using a lower dose maintenance strategy similar to the FDA approved dosing for MDS. The maintenance phase will include standard dose reductions for unacceptable toxicities.
The invention discloses a stable liposome and a preparation method thereof. The liposome mainly comprises the following components of phosphatidylcholine, cholesterol, drugs, folic acid and carrier materials, wherein the mass ratio of the phosphatidylcholine, the cholesterol and the drugs is 1-5 : 1 : 0.1; the mass ratio of the folic acid and the drugs is 1 : 3-6; and the mass ratio of the carrier materials and phosphatidylcholine is 3 : 1. The method is simple in process, and is helpful for industrialized production. Particle sizes of the liposome can be effectively controlled by adjusting the ratio of lipid components and by extruding filter. The stability of the liposome can be greatly improved by adding folic acid; and the liposome with small and homogeneous particle sizes and with good stability can be obtained, so that the application value of the liposome is greatly increased. An effect of moistening skins for a long time can be achieved via a transdermal delivery in a liposome way by using allocatechin gallate liposome prepared by the method of the invention.
Intimate partner violence is a serious public health problem that disproportionately affects drug-involved female offenders under community supervision. Moreover, accumulating research has found strong associations linking experiencing intimate partner violence (IPV) and continued drug use among women in drug treatment. This research suggests that failure to prevent IPV among drug-involved female offenders under community supervision likely to result in higher rates of relapse, treatment attrition and recidivism and underscores the need to address the IPV service needs among the rapidly growing population of female offenders under community supervision. Computerized multimedia IPV prevention service tools have been shown to be feasible and effective in conducting screening, brief intervention and referral for IPV in medical care settings. The proposed services research addresses the significant public health problem of IPV victimization and a co-occurring risk for relapse and recidivism among drug-involved female offenders under court supervision or probation. The proposed computerized tool employs a self-paced, multimedia format to conduct IPV screening, brief intervention and IPV-related service referrals that is informed by best IPV screening and referral practices and previous intervention research. This innovative tool represents a cost-effective option that may implemented with greater fidelity and result in better client satisfaction and IPV prevention outcomes. Furthermore, if found to be effective in identifying IPV and improving linkage to IPV services, this cost effective computerized service tool may be scaled up with ease and speed in court and probation settings in New York State and nationwide.
Tofranil™ is supplied in tablet form for oral administration.

Tofranil, imipramine hydrochloride USP, the original tricyclic antidepressant, is a member of the dibenzazepine group of compounds. It is designated 5-3-(dimethylamino)propyl-10,11-dihydro-5H-dibenz [b,f]-azepine monohydrochloride. Its structural formula is:

Imipramine hydrochloride USP is a white to off-white, odorless, or practically odorless crystalline powder. It is freely soluble in water and in alcohol, soluble in acetone, and insoluble in ether and in benzene.

Inactive Ingredients: Calcium phosphate, cellulose compounds, docusate sodium, iron oxides, magnesium stearate, polyethylene glycol, povidone, sodium starch glycolate, sucrose, talc, and titanium dioxide.